Skip to main content

Table 5 Changes from baseline in Work Productivity and Activity Index for Spondyloarthritis scores at weeks 16 and 52 for tumor necrosis factor inhibitor-experienced patients (COAST-W study)

From: Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Absenteeisma
Week 16   PBO (N = 104) IXE Q4W (N = 114) IXE Q2W (N = 98)
Nx 57 47 46
LSM (SE) − 1.2 (2.8) − 4.7 (2.9) − 6.9 (3.1)
Mean (SD) − 2.6 (28.6) − 7.5 (20.2) − 8.0 (24.2)
Week 52   PBO/IXE (N = 93) IXE Q4W/IXE Q4W (N = 98) IXE Q2W/IXE Q2W (N = 90)
Nx 49 45 46
Mean (SD) − 6.7 (26.2) − 11.8 (25.9) − 10.0 (27.1)
Presenteeisma
Week 16   PBO (N = 104) IXE Q4W (N = 114) IXE Q2W (N = 98)
Nx 54 44 43
LSM (SE) − 8.9 (3.6) − 19.5 (3.9)* − 22.2 (4.1)*
Mean (SD) − 8.8 (32.7) − 21.3 (23.6) − 25.6 (26.5)
Week 52   PBO/IXE (N = 93) IXE Q4W/IXE Q4W (N = 98) IXE Q2W/IXE Q2W (N = 90)
Nx 47 42 43
Mean (SD) − 24.0 (33.3) − 22.4 (25.6) − 27.2 (27.0)
Overall work impairmenta
Week 16   PBO (N = 104) IXEQ4W (N = 114) IXEQ2W (N = 98)
Nx 54 44 43
LSM (SE) − 9.8 (3.7) − 21.0 (4.0)* − 23.5 (4.2)*
Mean (SD) − 9.8 (32.8) − 23.0 (24.2) − 26.3 (26.8)
Week 52   PBO/IXE (N = 93) IXE Q4W/IXE Q4W (N = 98) IXE Q2W/IXE Q2W (N = 90)
Nx 47 42 43
Mean (SD) − 24.5 (33.1) − 24.1 (26.3) − 26.7 (27.6)
Activity impairment
Week 16   PBO (N = 104) IXE Q4W (N = 114) IXE Q2W (N = 98)
Nx 99 112 96
LSM (SE) − 10.1 (2.6) − 16.5 (2.4) − 18.4 (2.7)*
Mean (SD) − 8.3 (29.4) − 20.2 (23.9) − 21.2 (28.0)
Week 52   PBO/IXE (N = 93) IXEQ 4W/IXE Q4W (N = 98) IXE Q2W/IXE Q2W (N = 90)
Nx 89 98 90
Mean (SD) − 21.7 (28.4) − 24.6 (24.8) − 23.1 (26.2)
  1. LSM (SE) is from analysis of covariance (ANCOVA), with missing data imputed via modified baseline observation carried forward (mBOCF). Mean (SD) at week 16 is from observed data from the blind-dose extended treatment group. Mean (SD) at week 52 is presented with missing data imputed via mBOCF
  2. ANCOVA analysis of covariance, IXE Q4W 80 mg ixekizumab every 2 weeks, IXE Q4W 80 mg ixekizumab every 4 weeks, LSM least squares mean, mBOCF modified baseline observation carried forward, N number of patients in the treatment group, Nx number of patients in the analysis subgroup, PBO placebo
  3. p values were from ANCOVA (treatment vs. placebo) for week 16: *p < 0.05, p < 0.01, p < 0.001
  4. aAbsenteeism, presenteeism, and overall work impairment were measured in patients reporting part- or full-time work
  5. bAt week 16, patients receiving placebo (PBO) (COAST-V, COAST-W) or adalimumab (ADA) (COAST-V) were switched to ixekizumab (IXE) Q4W or Q2W. Data for IXE Q4W and IXE Q2W were combined for the PBO/IXE and ADA/IXE groups